Sublinox approved in Canada The Canadian regulatory authority (Health Canada) has approved Sublinox for treatment of insomnia. Sublinox is a new and patented sublingual product with the well known substance zolpidem. The product will be commercialized by the joint venture between Meda and Valeant (Meda Valeant Pharma Canada Inc.). Sublinox launch is expected to begin during the fourth quarter of 2011. “I'm pleased that we have now received our second product approval in Canada. We look forward to strengthen our joint venture with Valeant in Canada”, says Anders Lönner, CEO of Meda. For further inquiries, please contact: Anders Larnholt, Vice President Corporate Development & IR ph: 46 709-458 878
Sublinox approved in Canada
| Source: Meda AB